- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacogenomics and histone deacetylase inhibitors
Authors
Keywords
-
Journal
PHARMACOGENOMICS
Volume 17, Issue 16, Pages 1807-1815
Publisher
Future Medicine Ltd
Online
2016-10-21
DOI
10.2217/pgs-2016-0113
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of UGT2B7 Genetic Polymorphisms on Serum Concentrations of Valproic Acid in Chinese Children With Epilepsy Comedicated With Lamotrigine
- (2016) Qiuning Wang et al. THERAPEUTIC DRUG MONITORING
- The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients
- (2015) Yin-xiang Sun et al. EPILEPSY RESEARCH
- Effects ofUGT1A1genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer
- (2015) Andrew K. L. Goey et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Histone deacetylase inhibitors modulate KATP subunit transcription in HL-1 cardiomyocytes through effects on cholesterol homeostasis
- (2015) Naheed Fatima et al. Frontiers in Pharmacology
- A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
- (2014) A. Thomas et al. CLINICAL CANCER RESEARCH
- UDP-glucuronosyltransferase 2B17 genotype and the risk of lung cancer among Austrian Caucasians
- (2013) Michaela Gruber et al. Cancer Epidemiology
- Electrocardiographic Studies of Romidepsin Demonstrate Its Safety and Identify a Potential Role for KATP Channel
- (2013) A. M. Noonan et al. CLINICAL CANCER RESEARCH
- Valproic acid pathway
- (2013) Yogita Ghodke-Puranik et al. Pharmacogenetics and Genomics
- Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients
- (2013) Ling-Zhi Wang et al. PLoS One
- Influence of Uridine Diphosphate Glucuronosyltransferase 2B7 −161C>T Polymorphism on the Concentration of Valproic Acid in Pediatric Epilepsy Patients
- (2013) Kazuyuki Inoue et al. THERAPEUTIC DRUG MONITORING
- Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia
- (2012) M. Gruber et al. BLOOD
- Effects of UGT1A6, UGT2B7, and CYP2C9 Genotypes on Plasma Concentrations of Valproic Acid in Chinese Children with Epilepsy
- (2012) Yingjie Guo et al. Drug Metabolism and Pharmacokinetics
- Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients
- (2012) Xiao-Man Chu et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid
- (2012) Dimitrios Chatzistefanidis et al. PHARMACOGENOMICS
- Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor
- (2011) Paul Hamberg et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors
- (2011) Michael D. Shultz et al. JOURNAL OF MEDICINAL CHEMISTRY
- Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer
- (2011) Nan-Soon Wong et al. Pharmacogenetics and Genomics
- Association of genetic variants in six candidate genes with valproic acid therapy optimization
- (2011) Chin-Chuan Hung et al. PHARMACOGENOMICS
- Impact of ABCB1 Allelic Variants on QTc Interval Prolongation
- (2010) T. M. Sissung et al. CLINICAL CANCER RESEARCH
- Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk
- (2010) Z.-Y. Hu et al. CLINICAL CANCER RESEARCH
- Conformational Refinement of Hydroxamate-Based Histone Deacetylase Inhibitors and Exploration of 3-Piperidin-3-ylindole Analogues of Dacinostat (LAQ824)
- (2010) Young Shin Cho et al. JOURNAL OF MEDICINAL CHEMISTRY
- A pharmacogenetic study of vorinostat glucuronidation
- (2010) Soonmo Peter Kang et al. Pharmacogenetics and Genomics
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
- (2009) Peter Atadja CANCER LETTERS
- Characterization of UGTs Active against SAHA and Association between SAHA Glucuronidation Activity Phenotype with UGT Genotype
- (2009) R. M. Balliet et al. CANCER RESEARCH
- Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma
- (2009) S. Woo et al. CLINICAL CANCER RESEARCH
- Effect of Aging on Glucuronidation of Valproic Acid in Human Liver Microsomes and the Role of UDP-Glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10
- (2008) U. A. Argikar et al. DRUG METABOLISM AND DISPOSITION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started